New biomarker strategy aims to boost esophageal cancer treatment before surgery
NCT ID NCT06601309
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study tests a treatment plan based on a biomarker (CPS score) given before surgery for people with a certain type of esophageal cancer. About 90 adults with resectable, locally advanced esophageal squamous cell carcinoma will receive this tailored neoadjuvant therapy. The main goal is to see if this approach increases the number of patients who have no cancer cells left in their removed tissue after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.